Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements.
Two hundred patients with acute nonlymphocytic leukaemia received remission induction therapy consisting of cytosine arabinoside and an anthracycline antibiotic. Analysis of the pretherapy characteristics of the patients demonstrated that patient age was the most important factor in determining whether or not the patient would survive remission induction therapy. Assessment of the characteristics of the bone marrow after 6 d of therapy permitted the recognition of patients who were likely to fail to enter remission because of persistent leukaemia. Taken together, these observations demonstrate that it is possible to identify patients for whom conventional chemotherapy is not likely to be of benefit either because it is too intensive or because it is not intensive enough to produce a complete remission.
Preisler
H D
HD
Priore
R
R
Azarnia
N
N
Barcos
M
M
Raza
A
A
Rakowski
I
I
Vogler
R
R
Winton
E L
EL
Browman
G
G
Goldberg
J
J
D000208:Acute Disease; D000367:Age Factors; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D003561:Cytarabine